Participants 61 117 6
bone metastases in patients with advanced breast cancer:
Participants 325 430 6
 delaying or preventing skeletal-related events (SREs) in patients with breast cancer with bone metastase
Participants 453 689 3
 Patients were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo (n = 1,020) every 4 week
